Physician profile
Patrick R Hanley
NPI 1053631291
$1,463.53
in general payments reported to CMS, 2019-2025
16 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $220 · 2021: $48.20 · 2022: $15.63 · 2023: $117 · 2024: $593 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $355.45 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $299.90 | 2024 | |
| Novo Nordisk INC | $259.92 | 2019-2024 | |
| Abbvie INC. | $160.47 | 2021-2025 | |
| Eurofins Viracor, LLC | $107.91 | 2020 | |
| Insulet Corporation | $71.40 | 2022-2025 | Omnipod |
| Medtronic, INC. | $32.17 | 2023-2025 | Minimed 780g |
| Azurity Pharmaceuticals, INC. | $27.04 | 2025 | Triptodur |
| Neurocrine Biosciences, INC. | $26.04 | 2025 | |
| Eton Pharmaceuticals, INC. | $24.74 | 2024 | Alkindi |
| Soleno Therapeutics, INC. | $22.53 | 2025 | Vykat Xr |
| Pfizer INC. | $21.86 | 2025 | |
| Ascendis Pharma Endocrinology INC | $19.41 | 2024 | |
| Sequel Med Tech, LLC | $18.56 | 2025 | Twiist |
| Allergan, INC. | $16.13 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.